President Trump’s executive order seeks to significantly lower prescription drug costs, placing GOP lawmakers in a challenging position regarding government pricing strategies for pharmaceuticals.
Republican leaders, like Senate Majority Leader John Thune and Senate GOP Whip John Barasso, have expressed concerns that federal intervention in drug pricing could hinder innovation and restrict patient access to crucial therapies.
Now, they face a difficult task in responding to Trump’s recent actions.
The pharmaceutical industry, which has supported members from both parties, cautions that Trump’s proposed changes could jeopardize significant investments in research and development.
Thune remarked that Trump’s order is likely to stir controversy within Congress, reflecting a longstanding skepticism among Republicans about leveraging Medicare’s buying power to force pharmaceutical companies to reduce prices.
“If we were doing this, it would probably be quite controversial here… legislatively,” Thune commented on the situation.
The executive order instructs the Secretary of Health and Human Services to coordinate with the Centers for Medicare and Medicaid Services to communicate preferred price targets to pharmaceutical manufacturers, and ensure that American patients have access to prices similar to those in other developed countries.
This directive includes drugs under Medicare and Medicaid, as well as those associated with private insurance.
When questioned about the president’s initiative, Senate Judiciary Committee Chair Chuck Grassley shifted focus to his own legislation aimed at prohibiting “deceptive and unfair pricing practices” by pharmacy benefit managers.
“If we can pass my PBM bill, we could lower drug prices just as effectively, and that’s what I’m concentrating on,” he stated.
This perspective aligns more closely with the pharmaceutical industry’s view on the primary drivers of high drug prices.
Stephen J. UBL, the head of PhRMA, pointed out in a statement that industry players such as PBMs, insurance companies, and hospitals currently take a large share of drug spending.
He noted that the “money going to the intermediaries” in the U.S. often surpasses European pricing.
Senator James Lankford expressed concerns about the impact on research and development and indicated that he needs more time to examine the specifics of Trump’s proposals.
“I haven’t looked over all the details yet,” he noted. “We want to ensure that we continue supporting research and development in the U.S., so the specifics matter.”
Even amidst considerable pushback from Senate Republicans against what many term a “price fix,” Thune acknowledged Trump’s strong desire to reduce drug costs, even if it diverges from typical conservative policy approaches.
“He clearly wants to see drug prices decrease, and I think it’s a long-held belief of his,” Thune added.
During a press conference on Monday, Trump acknowledged that drug lobbies are extremely powerful but asserted that “from now on, the U.S. will no longer subsidize foreign healthcare,” and that the country won’t tolerate inflated profits from the pharmaceutical sector.
In 2024, the pharmaceutical industry reportedly spent $387 billion on lobbying efforts.
Trump attributed rising costs for American consumers to aggressive negotiation tactics by foreign entities, linking it to stories of supporters who paid significantly less for medications abroad than in the U.S.
In a post on Truth Social over the weekend, he claimed his order could reduce drug prices by as much as 30% to 80%.
He instructed GOP leaders to calculate savings from Medicare to aid in negotiating the costs associated with the budget adjustment package aimed at implementing tax cuts later this year.
“When you calculate, you have to account for the hundreds of billions in tariff revenue. Even more importantly, you need to consider the costs of Medicaid and Medicare.”
However, the idea of pressuring pharmaceutical companies to lower prices has traditionally been opposed by many Republicans, who argue it could slow patient access to necessary treatments.
Thune previously criticized demands for direct negotiations with drug manufacturers in legislation produced by the Democratic-controlled House, denouncing it as part of a broader push for government-run healthcare.
He acknowledged high drug prices as a concern but argued that “controlling the entire American health system” wouldn’t resolve the issue.
Thune claimed U.S. patients have access to 96% of new cancer treatments while those in countries with price controls, like Germany and France, face limitations.
He also pointed out a drastic decline in European investment in drug research since 1986, following the implementation of price controls.
Barasso recently cautioned that the introduction of Medicare drug price controls could negatively impact treatments for rare diseases, mentioning that such measures could stifle innovation.
Speaking to the Hill on Monday, Barasso emphasized the necessity of thoroughly examining Trump’s proposal.
“I need to assess the specifics of the proposal,” he remarked.
“Importing pricing from countries with socialist systems could be detrimental for American patients and workers,” UBL warned in a statement on Sunday.
He cautioned that this could lead to fewer treatment options, restricting opportunities for investment, threatening jobs, and resulting in reliance on China for innovative medications.
